AGENUS (AGEN) Covered Calls

AGENUS covered calls Antigenics, Inc. is a biotechnology company, which is developing and commercializing technologies to treat cancers and infectious diseases, based on immunological approaches.

You can sell covered calls on AGENUS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AGEN (prices last updated Fri 4:16 PM ET):

AGENUS (AGEN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.12 -0.12 2.11 2.15 658K - 0.2B
Covered Calls For AGENUS (AGEN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Aug 17 2 0.20 1.95 2.6% 32.7%
Nov 16 2 0.40 1.75 14.3% 43.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Agenus, Inc. is a biotechnology company, which is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by its licensees in numerous vaccines under development in clinical trials, some as advanced as phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus and tuberculosis. Agenus within its HSP Platform is developing its recombinant series and prophage series vaccines. The company's HerpV, a therapeutic vaccine candidate from the recombinant series, which contains QS-21 Stimulon, has been tested in a phase 1 clinical trial for the treatment of genital herpes. Agenus was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.